Novartis-backed eye therapy developer GenSight filed for a $100m offering in the US a year ago, only to withdraw in November.

The genomic medicine company initially raised $50m in an offering that enabled WuXi PharmaTech to exit, before its stock rose significantly post-IPO.

Two of Legend Holdings' investment units have exited the tyre manufacturer through the initial public offering, after taking part in a $15m round in 2010.

The WuXi PharmaTech-backed genomic medicine developer floated below its range, after raising $125m in venture capital.

The messaging service has set its range at $26.50 to $31.50 per share, potentially raising $1.1bn when it floats in Tokyo and New York next month.

Sanofi-backed Selecta Biosciences had raised $117m prior to the offering, and will use the proceeds to advance its gout treatment through clinical trials.

The business communication technology provider, which had raised $240m from investors including Amazon and Salesforce, will float above its range.

Naver-owned messaging platform Line is set to sell 13 million shares in Japan and 22 million shares in the US priced at $26.30 each for a dual listing.

Internet Thailand intends to keep its 25% stake in the Thailand-based back-office services provider.

The initial public offering on Aim will provide an exit to shareholders including Novartis, which gave Mereo access to three of its clinical stage therapies last year.